Vor Biopharma Inc. Common Stock
VORStock
$17.34−61.30%52W
Market Cap$979.68M
P/E—
Div yield—
Beta1.61
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)49.85%
Price vs S&P 500 (4W)31.88%
VGM Score48.78
Market Capitalization$979.68M
Earnings Surprise History
Q1 26-5.11est. -0.79
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.23
4.23
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VORVor Biopharma Inc. Common Stock | — | — | C | $17.34 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Vor Biopharma is a clinical-stage cell therapy company developing engineered cell therapies for hematological malignancies using proprietary patient engineering technology. The company's lead programs include VCAR33 and Tremcel, with additional candidates targeting CD123, CLL1, and EMR2 markers for blood cancers and myelodysplastic syndrome.